🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

KEYNOTE-966 GemCis+/-Pembro 1L BTC ▶️GC-Pem OS 12.7m v 10.9m (sig) ▶️ORR 29% in both, PFS ns but favors GC-Pem TOPAZ Differences ❇️stratified by geography ❇️gem maintenance ❇️blinded central review of response 🔥Solidifies GC+IO in 1L. Work to be done. 🔥If doing well, keep Gem

#AEEH2025. ➡️'Hepatolotoxicidad por inhibidores de CDK4/6 en cáncer de mama metastático (CMM)', con Mar Riveiro (ganadora de una de las #Becas Gilead-AEEH). ✔️Un estudio multicéntrico que todavía está en marcha. 🗣️"El manejo del #DILI por CDKi es heterogéneo, y su

🔥CHMP recommended a conditional marketing authorisation for zanidatamab for the treatment of HER2-positive biliary tract cancer🔥 👉based on HERIZON-BTC: ORR 41% 👉Phs-III in 1st line ongoing ESMO - Eur. Oncology EASL Education ILCA Cholangiocarcinoma Foundation @livertwitter

👏 Celebrating the strong contribution of our researchers from #VHIO’s Hereditary Cancer Genetics Group, led by judith balmaña, at #BRCA2025 in Montreal. 🎯 Advancing prevention and treatment in hereditary cancer through science and dedication.

The present and the future of immunotherapy in hepatocellular carcinoma and biliary tract cancers 💥Great review (Note: Medical writing support by Edra S.p.A. & AstraZeneca!) cancertreatmentreviews.com/article/S0305-…

🔥EASL Clinical Practice Guidelines on the management of extrahepatic cholangiocarcinoma🔥 Journal of Hepatology doi.org/10.1016/j.jhep… 👉get the lastest update on the diagnosis and management of eCCA ESMO - Eur. Oncology EASL Education ILCA #livertwitter

We all know Jaume Capdevila magnificent presentation about Obrixtamig in epNECs. But let's go further! The first time the cut-off point of DLL3 positivity is revealed. We know it for Tarlatamab in SCLC? Is it better % or H-score? What do you think? Grupo GETNE ENETS NANETS

📢Practice-changing in 2L HER2+ GOJ/GC: DESTINY-Gastric04 trial 👁️T-Dxd vs paclitaxel+ramucirumab 🎯14.7 vs 11.4 m; HR 0.70 (p=0.004) ⚠️ILD/pneumonitis in 14% (mostly G1/2) 👣an exciting future to walk through with studies testing T-Dxd and zanidatamab upfront 📄NEJM today

PANOVA-3: TTFields plus GnP vs GnP for LA-PDAC #ASCO25 mOS 16.2 vs 14.2 m, HR 0.82 Median Pain-free survival 15.2 vs 9.1 m

Perioperative radiochemotherapy vs Gem/Cis in locally advanced gallbladder cancers #ASCO25 🔎POLCAGB phs-III 👉ORR 74% vs 35% 👉mEFS 10 vs 4.8 mo 👉mOS 21.8 vs 10 mo 🧐 small trial, but very interesting efficacy data in cT3/4 cN+ ESMO - Eur. Oncology @easledu ILCA Cholangiocarcinoma Foundation

🔴 Addition of Tumor Treating Fields to standard chemotherapy improves survival and pain-free survival in locally advanced pancreatic adenocarcinoma Findings co-authored by Teresa Macarulla presented at #ASCO25 & published in Journal of Clinical Oncology.  👉 linke.to/PANOVA-3ASOC25… ASCO

🔬 Three important cancer trials from #ASCO25, published today in NEJM. New findings in gastric, breast, and colon cancer. Quick highlights 👇 1-MATTERHORN (ASCO) In resectable gastric/GEJ cancer, adding perioperative durvalumab to FLOT improved 2-year event-free survival (67%

🔥Plenary Discussion of LBA5🔥 📷 #ASCO2025 👏Great discussion by Sam Klempner 👉D-FLOT reached it's primary endpoint and will change clinical practice 👉More to come: from MATTERHORN to EVEREST ESMO - Eur. Oncology

Excellent summary slides for current evidence for pancreatic cancer treatment . Useful for quick reference. @asco #asco25 taken from talk by Dr Brian Wolpin 👍OncoAlert ONCO BRUNO

Couldn’t be prouder of you, Virginia Genovesi Congrats on presenting our study on ER in resected PDAC and for the travel grant! Key findings ⬇️ • 66% relapsed <1 yr • ER = worse OS • pT3–4 tumors more common in ER • KRAS mut (non-G12R) ↑ in ER Vall d’Hebron Institute of Oncology (VHIO) ESMO - Eur. Oncology #ESMOGI25

John Bridgewater presented the results of ProvIDHe study, ivosidenib in the real world setting achieved a mPFS 4,7 months and mOS 15.5 months #ESMOAmbassadors ESMO - Eur. Oncology #ESMOGI25

💊Classes of KRAS inhibitors #ESMOGI25 ESMO - Eur. Oncology #cancer #oncology #MedX